Respiratory syncytial virus (RSV) is a common cause of respiratory illness in infants and young children, as well as older adults. Each season, RSV causes morbidity and mortality in older adults, including lower respiratory tract disease, hospitalisation and death.

Arexvy is a new vaccine that causes the immune system to produce RSV antibodies. It includes an adjuvant which is a component that enhances the immune response to the vaccination.

Arexvy is currently approved as a single dose to protect against symptomatic lower respiratory tract disease caused by RSV in adults aged 60 years and older.  The need for revaccination has not been established, but evidence shows protection for at least two RSV seasons.

Those adults aged 60 years and older who are at higher risk of severe RSV disease include:

• People with moderate or severe immune compromise

• People who are frail

• People aged over 80 years

• People living in nursing homes or other long-term care facilities

Common responses to the vaccine include:

• Headache

• Muscle and joint pain

• Infection site pain

• Fatigue

• Nausea

Rare responses:

• Hypersensitivity (e.g. rash)

If you are wishing for an Arvexy vaccine please contact us to discuss.
Arexvy is privately funded vaccine and the current cost is $362.20